Connect Biopharma is trading 7.62% up at $2.40 in pre-market after no new company-specific catalyst was identified for August 31, 2026.
- Its latest material update was the August 12 second-quarter report, which said enrollment was complete in two Phase 2 Seabreeze STAT studies.
- Topline results were expected in September 2026; the broader market is mixed, so macro sentiment does not clearly explain the move.
- Confidence is low pending further filings or company news.